COMP <GO>
ENOV vs UNH // REVENUE GROWTH (YOY)
Enovis Corporation (NYSE) VS. UnitedHealth Group Incorporated (NYSE) • 15-METRIC TALLY: ENOV 1
— UNH 9
▲ REVENUE GROWTH (YOY) LEADER: ENOV
LAST: $22.81 (+4.11%) • MKT CAP: $1.32B
revenue-growth
6.70%
LAST: $410.91 (+0.94%) • MKT CAP: $368.83B
revenue-growth
6.46%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ENOV VS. UNH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ENOV | UNH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 59.80% | 88.57% | -28.77 | UNH | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -32.70% | 11.47% | -44.17 | UNH | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 16.4x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 1.51% | 6.48% | -4.97 | UNH | /fcf-yield <GO> |
| Operating Margin | -50.00% | 4.82% | -54.82 | UNH | /operating-margins <GO> |
| Net Profit Margin | -52.70% | 3.14% | -55.84 | UNH | /net-margins <GO> |
| Revenue Growth (YoY) ACTIVE | 6.70% | 6.46% | +0.24 | ENOV | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.28% | -2.28 | UNH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.20 | 3.12 | -2.92 | UNH | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 7/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 6.74% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 48.3 | 59.2 | -10.92 | UNH | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.33 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 17.1x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.32B | $368.83B | -$367.52B | UNH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ENOV REV | UNH REV | ENOV GROSS % | UNH GROSS % | ENOV FCF | UNH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $2.25B | $447.57B | 59.8% | 88.7% | $19.9M | $16.07B |
| FY 2024 | $2.11B | $400.28B | 56.0% | 88.3% | -$67.2M | $20.70B |
| FY 2023 | $1.71B | $371.62B | — | 89.6% | $135.0M | $25.68B |
| FY 2022 | — | $324.16B | — | 89.6% | — | $23.40B |
| FY 2021 | — | $287.60B | — | 89.2% | — | $19.89B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ENOV // BETA —
UNH // BETA 0.33